Pfizer, Inc. announced positive topline results from a Phase III study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate receptor modulator in development for the treatment of moderately to severely active ulcerative colitis.
[Pfizer, Inc.]
Sorry, but the selected Zotpress account can't be found.
